OptiNose has announced that Keith A. Goldan has joined the company as Chief Financial Officer. Goldan was most recently Senior VP and CFO of Fibrocell and previously served as CFO at NuPathe, PuriCore (now Realm Therapeutics), and Biosyn. The announcement comes a few months after the company announced the appointment of Tom Gibbs as Chief Commercial Officer.
In late 2015, OptiNose announced that it had raised up to $30 million for continued development and commercialization of its OPN-375 intranasal fluticasone. The company is also developing intranasal oxytocin for the treatment of autism.
OptiNose CEO Peter Miller said, “With Keith’s appointment, we continue to solidify our leadership team with experienced biopharma executives able to transition the company from development to commercial stage. Keith has an exemplary track record of financial leadership and value creation for companies of all sizes, and he will be critical to our efforts to ensure we are appropriately capitalized as we build OptiNose into a leading ENT/Allergy specialty company.”
Goldan commented, “OptiNose is at a pivotal stage in its evolution as it prepares for the commercialization of OPN-375. I am excited and honored to join this outstanding team. OPN-375 has the potential to help millions of chronically suffering patients, and I look forward to working hard to create long-term value for them and all of our stakeholders.”
Read the OptiNose press release.
